{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:34Z","timestamp":1787008774801,"version":"build-2736575974"},"reference-count":39,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypertriglyceridaemia is an established risk factor for cardiovascular disease and acute pancreatitis with postprandial elevations as an important contributor. Olezarsen, an investigational antisense oligonucleotide targeting plasma apolipoprotein C-III, markedly reduces fasting triglyceride levels, though its effect on postprandial triglyceride levels remains to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In a double-blind, placebo-controlled trial, 28 patients with fasting triglycerides \u2265 4\u2005mmol\/L received either two doses 80\u2005mg olezarsen (19 patients) or placebo (9 patients) every 4 weeks. Triglyceride levels were measured in the fasting state and postprandially both at baseline and 7 weeks into treatment. Postprandial triglyceride levels were assessed by calculating the area under the curve (AUC). The mean (\u00b1SD) age was 58.6 \u00b1 9.4 years, 82.1% (23) were male, and the median [IQR] baseline fasting triglyceride levels were 5.9 [4.5, 9.2] mmol\/L. At 7 weeks, olezarsen treatment led to a placebo-adjusted triglyceride reduction of 59.3% (\u221277.3 to \u221241.2%, P &amp;lt; 0.0001). The mean [95% confidence interval (CI)] postprandial placebo-adjusted triglyceride AUC was reduced by 50.1% (\u221268.3 to \u221231.8%, P &amp;lt; 0.0001). Mean (95% CI) incremental AUC (iAUC) was reduced by 30.3% (\u221256.2 to \u22124.3%, P = 0.026) in the olezarsen vs. baseline group; the placebo-adjusted iAUC remained unchanged. The proportion of patients reaching any triglyceride levels \u2265 10\u2005mmol\/L, indicative of increased risk estimation of acute pancreatitis, decreased from 47 to 5% after olezarsen treatment, a 96.6% (P &amp;lt; 0.0001) reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Olezarsen significantly reduces both fasting and postprandial triglyceride levels; these findings highlight olezarsen as a promising intervention to managing hypertriglyceridaemia and reducing the risk of hypertriglyceridaemia-induced acute pancreatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwaf478","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:32:40Z","timestamp":1753788760000},"source":"Crossref","is-referenced-by-count":9,"title":["Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: results from a randomized trial"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7566-6403","authenticated-orcid":false,"given":"Jordan M","family":"Kraaijenhof","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, Amsterdam 1105AZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merel C","family":"Peletier","sequence":"additional","affiliation":[{"name":"Department of Experimental Vascular Medicine, Amsterdam UMC Location University of Amsterdam , Meibergdreef 9, Amsterdam ,","place":["Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-6009","authenticated-orcid":false,"given":"Nick S","family":"Nurmohamed","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, Amsterdam 1105AZ ,","place":["The Netherlands"]},{"name":"Department of Cardiology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, Amsterdam 1105AZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica J","family":"Alexander","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals , Carlsbad, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals , Carlsbad, CA ,","place":["USA"]},{"name":"Division of Cardiology, Department of Medicine, University of California San Diego , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7584-7677","authenticated-orcid":false,"given":"Erik S G","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Centers, University of Amsterdam , Meibergdreef 9, Amsterdam 1105AZ ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9983-6614","authenticated-orcid":false,"given":"Jeffrey","family":"Kroon","sequence":"additional","affiliation":[{"name":"Department of Experimental Vascular Medicine, Amsterdam UMC Location University of Amsterdam , Meibergdreef 9, Amsterdam ,","place":["Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025081304070223700_zwaf478-B1","first-page":"1","article-title":"Global burden of cardiovascular diseases: projections from 2025 to 2050","author":"Chong","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2025081304070223700_zwaf478-B2","first-page":"1","article-title":"Remnant cholesterol, plasma triglycerides and risk of cardiovascular disease events in young adults: a prospective cohort study","author":"Aaseth","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2025081304070223700_zwaf478-B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"2025081304070223700_zwaf478-B4","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2025081304070223700_zwaf478-B5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/2050640618755002","article-title":"Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management","volume":"6","author":"de Pretis","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"2025081304070223700_zwaf478-B6","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.3390\/jcm9123954","article-title":"Incidence and management of hypertriglyceridemia-associated acute pancreatitis: a prospective case series in a single Australian Tertiary Centre","volume":"9","author":"Tan","year":"2020","journal-title":"J Clin Med"},{"key":"2025081304070223700_zwaf478-B7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025081304070223700_zwaf478-B8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"The Lancet"},{"key":"2025081304070223700_zwaf478-B9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"J Am Med Assoc"},{"key":"2025081304070223700_zwaf478-B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2011.08.012","article-title":"Postprandial lipemia and cardiovascular disease risk: interrelationships between dietary, physiological and genetic determinants","volume":"220","author":"Jackson","year":"2012","journal-title":"Atherosclerosis"},{"key":"2025081304070223700_zwaf478-B11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.46747\/cfp.6912849","article-title":"Reducing pancreatitis risk in patients with hypertriglyceridemia","volume":"69","author":"MacDonald","year":"2023","journal-title":"Can Fam Physician"},{"key":"2025081304070223700_zwaf478-B12","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"2025081304070223700_zwaf478-B13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025081304070223700_zwaf478-B14","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"2025081304070223700_zwaf478-B15","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"2025081304070223700_zwaf478-B16","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"2025081304070223700_zwaf478-B17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/01.CIR.100.7.723","article-title":"Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-Media thickness in healthy, middle-aged men","volume":"100","author":"Boquist","year":"1999","journal-title":"Circulation"},{"key":"2025081304070223700_zwaf478-B18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/ATVBAHA.110.215434","article-title":"CD11c\/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1","volume":"31","author":"Gower","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025081304070223700_zwaf478-B19","doi-asserted-by":"crossref","first-page":"831435","DOI":"10.3389\/fendo.2022.831435","article-title":"Identification of the Chinese population that can benefit most from postprandial lipid testing: validation of the use of oral fat tolerance testing in clinical practice","volume":"13","author":"Hou","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025081304070223700_zwaf478-B20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/1570161117666190507110519","article-title":"Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 expert panel statement, main text","volume":"17","author":"Kolovou","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"2025081304070223700_zwaf478-B21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025081304070223700_zwaf478-B22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"2025081304070223700_zwaf478-B23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia","volume":"9","author":"Gaudet","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025081304070223700_zwaf478-B24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"2025081304070223700_zwaf478-B25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2025081304070223700_zwaf478-B26","doi-asserted-by":"crossref","first-page":"EVIDoa2200325","DOI":"10.1056\/EVIDoa2200325","article-title":"RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia","volume":"2","author":"Gaudet","year":"2023","journal-title":"NEJM Evid"},{"key":"2025081304070223700_zwaf478-B27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2012.02.001","article-title":"Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity","volume":"222","author":"Adiels","year":"2012","journal-title":"Atherosclerosis"},{"key":"2025081304070223700_zwaf478-B28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1203\/00006450-200111000-00013","article-title":"Postprandial chylomicron clearance rate in late teenagers with diabetes Mellitus type 1","volume":"50","author":"Van Waarde","year":"2001","journal-title":"Pediatr Res"},{"key":"2025081304070223700_zwaf478-B29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ejcn.1602749","article-title":"Methodology for studying postprandial lipid metabolism","volume":"61","author":"Lairon","year":"2007","journal-title":"Eur J Clin Nutr"},{"key":"2025081304070223700_zwaf478-B30","doi-asserted-by":"crossref","first-page":"e160607","DOI":"10.1172\/jci.insight.160607","article-title":"Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations","volume":"7","author":"Taskinen","year":"2022","journal-title":"JCI Insight"},{"key":"2025081304070223700_zwaf478-B31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jshs.2021.07.006","article-title":"Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: a systematic review and network meta-analysis","volume":"11","author":"Alvarez-Jimenez","year":"2022","journal-title":"J Sport Health Sci"},{"key":"2025081304070223700_zwaf478-B32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jacl.2022.10.006","article-title":"Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia","volume":"17","author":"Heidemann","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2025081304070223700_zwaf478-B33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00129784-200808040-00004","article-title":"Therapeutic effects of fibrates in postprandial lipemia","volume":"8","author":"Kolovou","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"2025081304070223700_zwaf478-B34","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dc07-0015","article-title":"Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome","volume":"30","author":"Rosenson","year":"2007","journal-title":"Diabetes Care"},{"key":"2025081304070223700_zwaf478-B35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0026-0495(03)00155-0","article-title":"Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects","volume":"52","author":"Carstensen","year":"2003","journal-title":"Metabolism"},{"key":"2025081304070223700_zwaf478-B36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025081304070223700_zwaf478-B37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.pan.2020.06.005","article-title":"Hypertriglyceridemia and acute pancreatitis","volume":"20","author":"Yang","year":"2020","journal-title":"Pancreatology"},{"key":"2025081304070223700_zwaf478-B38","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.3748\/wjg.14.4558","article-title":"Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis","volume":"14","author":"Deng","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2025081304070223700_zwaf478-B39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf478\/63890461\/zwaf478.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf478\/63890461\/zwaf478.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:07:11Z","timestamp":1755072431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwaf478\/8218914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf478","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"zwaf478"}}